Corbus Pharma

Corbus Pharma Corbus (Nasdaq: CRBP) is connecting innovation to purpose to improve the futures of cancer and obesity patients.

03/11/2026

Our clinical development is focused on scientifically validated mechanisms that regulate appetite, energy use, and metabolic function. For more on Corbus' therapy pipeline, visit: https://bit.ly/40Lts1n

03/09/2026

"Our encouraging data readouts for CRB-701 and CRB-913 in the fourth quarter of 2025 set the stage for a potentially transformative 2026," said Yuval Cohen, Ph.D., Corbus CEO. Read more for key corporate and program updates: https://bit.ly/47i6aE8

03/09/2026

Corbus today provided a corporate update and reported financial results for the fourth quarter and year ended December 31, 2025. For details: https://bit.ly/47i6aE8

At Corbus, we are developing CRB-913, an experimental daily pill designed to selectively target the CB1 receptor to trea...
03/06/2026

At Corbus, we are developing CRB-913, an experimental daily pill designed to selectively target the CB1 receptor to treat life-long more safely and effectively. Learn more: https://bit.ly/4l73XRz

CRB-913

03/04/2026

Today is ! Obesity has become a global health crisis, doubling in prevalence since 1990 and significantly increasing the risk of heart disease, diabetes, certain cancers, and musculoskeletal disorders.

At Corbus, we are developing CRB-913, an experimental daily pill designed to selectively target the CB1 receptor to treat life-long obesity more safely and effectively. Learn more: https://bit.ly/40Lts1n

03/03/2026

Driven by lifestyle, genetics, and biological factors, now ranks as the fourth leading cause of preventable death worldwide. Effective and safe treatments are urgently needed to reverse this trend and improve quality of life. Learn about our development of CRB-913 for obesity: https://bit.ly/40Lts1n

Corbus is developing CRB-701 for the treatment of patients with advanced solid tumors known to be associated with high N...
02/26/2026

Corbus is developing CRB-701 for the treatment of patients with advanced solid tumors known to be associated with high Nectin-4 expression, such as and . Learn about CRB-701: https://bit.ly/3P1yp3y

CRB-701

02/24/2026

Reminder: Yuval Cohen, Ph.D., CEO of Corbus, will present a corporate overview at the 36th Annual Oppenheimer Healthcare Life Sciences Conference tomorrow, February 25th at 3:20pm ET. For webcast details: https://bit.ly/4rfWKkF

02/19/2026

Tune-in on Wednesday, February 25th at 3:20pm ET for Corbus CEO Yuval Cohen's presentation at the 36th Annual Oppenheimer Healthcare Life Sciences Conference. For webcast details: https://bit.ly/4rfWKkF

02/17/2026

Focused on oncology and obesity, Corbus is advancing three key investigational therapies designed to address significant unmet medical needs. Learn about our pipeline: https://bit.ly/4qEDo7u

02/12/2026

Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will present a corporate overview and attend investor meetings at the 36th Annual Oppenheimer Healthcare Life Sciences Conference, to be held virtually February 25-26, 2026 For details: https://bit.ly/4rKkfC1

01/14/2026

Reminder: Yuval Cohen, Ph.D., CEO of Corbus, will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference tomorrow at 8:15 a.m. PST/11:15am EST. For webcast details: https://bit.ly/4js7Obg

Address

500 River Ridge Drive, Second Floor
Norwood, MA
02062

Opening Hours

Monday 8:30am - 5:30pm
Tuesday 8:30am - 5:30pm
Wednesday 8:30am - 5:30pm
Thursday 8:30am - 5:30pm
Friday 9am - 5:30pm

Telephone

+16179630100

Website

Alerts

Be the first to know and let us send you an email when Corbus Pharma posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Corbus Pharma:

Shortcuts

Featured

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Our Story

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its industry leading pipeline of endocannabinoid system-targeting drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a 2nd generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist specifically designed to eliminate blood-brain barrier pe*******on and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis, among others. CRB-4001 is scheduled to enter a Phase 1 study in 2019 followed a National Institutes of Health (NIH)-funded first-in-patient Phase 2 study.